瑞银发表报告，列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单：股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) -0.160 (-0.356%) 沽空 $89.74万; 比率 3.484% │97%石药集团(01093.HK) +0.150 (+2.027%) 沽空 $1.04亿; 比率 17.635% │60%三生制药(01530.HK) +0.480 (+1.584%) 沽空 $8.92千万; 比率 17.277% │42%科济药业-B(02171.HK) +0.050 (+0.320%) 沽空 $1.03千万; 比率 11.190% │42%上石化(00338.HK) -0.010 (-0.746%) 沽空 $1.37百万; 比率 13.264% │37%越秀地产(00123.HK) +0.020 (+0.446%) 沽空 $3.71百万; 比率 24.221% │35%金风科技(02208.HK) +0.680 (+4.993%) 沽空 $3.33千万; 比率 8.398% │33%科伦博泰生物-B(06990.HK) -22.600 (-5.205%) 沽空 $8.46千万; 比率 13.397% │27%中信建投证券(06066.HK) +0.350 (+2.728%) 沽空 $8.41百万; 比率 6.539% │26%恒瑞医药(01276.HK) +0.150 (+0.207%) 沽空 $1.05亿; 比率 45.620% │25%海丰国际(01308.HK) +0.700 (+2.315%) 沽空 $4.12千万; 比率 30.167% │23%药明康德(02359.HK) +2.800 (+2.740%) 沽空 $9.41千万; 比率 22.561% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-11-06 16:25。)